Overview

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Status:
NOT_YET_RECRUITING
Trial end date:
2030-11-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Phase:
PHASE3
Details
Lead Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Collaborator:
Celgene Corporation
Treatments:
Cyclophosphamide
fludarabine
nintedanib
Rituximab
tocilizumab